|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 38/00 | (2006.01) |
| C12N 9/64 | (2006.01) |
| (11) | Number of the document | 2035445 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07873840.8 |
| Date of filing the European patent application | 2007-06-29 | |
| (97) | Date of publication of the European application | 2009-03-18 |
| (45) | Date of publication and mention of the grant of the patent | 2015-06-17 |
| (46) | Date of publication of the claims translation | 2015-09-25 |
| (86) | Number | PCT/US2007/015298 |
| Date | 2007-06-29 |
| (87) | Number | WO 2008/105797 |
| Date | 2008-09-04 |
| (30) | Number | Date | Country code |
| 818234 P | 2006-06-30 | US |
| (72) |
MINTIER, Gabriel, A., US
CHEN, Jian, US
FEDER, John, N., US
PARKER, Rex, A., US
MIAO, Bowman, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Polinukleotidai, koduojantys naujus PCSK9 variantus |
| POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS |
| Payment date | Validity (years) | Amount | |
| 2022-06-23 | 16 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2022-02-14 |